International Stem Cell Corp (ISCO) 1.9700

New Post Public Reply Private Reply Replies (0) Message Board

Aug 23, 2016 at 7:10 AM

International Stem Cell Corp (ISCO) 1.9700 $ISCO

International Stem Cell Corporation Announces Operating Results for the Three and Six-Months Ended June 30, 2016
GlobeNewswire - Tue Aug 16, 7:30AM CDT
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"

, the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO"

for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
CYRX: 2.10 (+0.10)

International Stem Cell Corporation Announces Operating Results for the Three-Months Ended March 31, 2016
Marketwired - Tue May 17, 7:31AM CDT
CARLSBAD, CA--(Marketwired - May 17, 2016) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"

, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three months ended March 31, 2016.

International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results
Marketwired - Thu Mar 31, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"

, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2015.

Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.42 (+0.01), ISIS: 57.56 (-0.28), ONCE: 58.35 (+1.10), SHPG: 200.63 (+0.81), SCMP: 11.49 (+0.18), GNST: (), CLBS: 5.42 (-0.03)

International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
Marketwire Canada - Wed Dec 23, 7:47AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson's disease (PD) patients. The Florey is one of the world's leading brain research centers, employing the largest neuroscience research team in Australia.

International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
Marketwired - Mon Dec 14, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a leader in using pluripotent stem cells in regenerative medicine, announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission of ISCO's wholly owned subsidiary, Cyto Therapeutics, to initiate a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson's disease (PD). Currently, there is no cure for PD, which is the second most common neurodegenerative disease and affects over 7 million people worldwide.

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Marketwire Canada - Tue Dec 01, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season.

International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015
Marketwired - Mon Nov 16, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"

, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2015.

International Stem Cell Corporation Moves Forward With Parkinson's Disease Clinical Trials in Australia
Marketwired - Tue Nov 03, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that after a recent meeting with Australian Therapeutics Goods Administration (TGA) the Company's wholly owned subsidiary Cyto Therapeutics signed a Letter of Intent (LOI) with Royal Melbourne Hospital (Australia) to conduct phase I/IIa clinical trials of ISCO's proprietary human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson's Disease. Under this process, a full agreement will be signed after TGA and the HREC approve the clinical protocol for the phase I/IIa trials.

U.S. Markets for Biologic and Tissue Engineered Devices 2015 - Cardiovascular and Neurological Products Analysis
M2 - Tue Oct 27, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fghmqn/u_s_markets_for) has announced the addition of the "U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products" report to their offering. Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases. Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives. Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.). The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention. Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts. Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer's disease, ischemic stroke, Parkinson's disease, and spinal cord injury. Content included in this report includes: - Emerging cellular therapies for cardiovascular and neurological diseases - Companies and biotech firms developing novel cellular therapies - A prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases - A speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies. Key Topics Covered: Executive Summary 1. Tissue Engineering and Cellular Therapy Tools and Techniques 1.1 Biomaterials 1.2 Cell Culture Technology 1.3 Stem Cell Technology 1.4 Immunoisolation Technology 2. Emerging Applications of Tissue Engineering and Cell Transplantation in Cardiovascular Disease Management 2.1 Cellular Therapy and Tissue Engineering 2.2 Cellular Therapy Administration 2.3 Clinical Experience with Stem Cell-Based Myocardial Tissue Repair and Regeneration 2.4 Cellular Therapies for Myocardial Repair and Regeneration in Development 2.5 Emerging Cellular Therapies for Limb Salvage in Critical Limb Ischemia Patients 2.6 Bioengineered Vascular Conduits 2.7 Current and Emerging U.S. Market for Cardiovascular Disease-Related Tissue Engineering and Cellular Therapy Products 3. Emerging Applications of Tissue Engineering and Cell Transplantation in Neurological Disease Management 3.1 Types of Cells Used for Cellular Therapies in Development 3.2 Emerging Stem Cell-Based Therapies for Alzheimer's Disease 3.3 Emerging Stem Cell-Based Therapies for Parkinson's Disease 3.4 Emerging Stem Cell-Based Therapies for Spinal Cord Injury 3.5 Emerging Stem Cell-Based Therapies for Post-Ischemic Stroke 3.6 Potential U.S. Market for Neurological Disease-Related Cellular Therapy Products Appendix: Company Listing Bibliography Companies Mentioned - Athersys - Baxter - Bioheart, Inc. - Biomet Biologics - Bukwang Pharmaceutical - Bundang CHA Hospital - Capricor Therapeutics - Chinese Academy of Military Medical Sciences - Cytori Therapeutics - Ecron Acunova - Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico - Harvest Technologies - Hospital Sao Rafael - Instituto de Medicina Regenerativa/Ageless Regenerative Institute - International Stem Cell Corporation - Medipost - Mesoblast Ltd. - NeoStem - Neuralstem - Neurogen Brain and Spine Insitute - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron, Ltd. - SanBio - StemCells, Inc. - Stemedica - Stempeutics - Taxus Cardium Pharmaceuticals Group - Terumo Corporation - The General Hospital of Chinese Armed Police Forces - Translational Biosciences - University of Irvine - Vericel For more information visit http://www.researchandmarkets.com/research/fg...arkets_for
CAPR: 3.60 (-0.06), PSTI: 1.67 (-0.06), CYTX: 2.19 (+0.03), OSIR: 5.20 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EPR Fireworks, Schedule2.IT Enhance EMS Integration

Joining Forces for Effective EMS Management In a move that could shake up emergency medical services, EPR Fireworks has teamed up with Schedule2.IT to amp up integration. This Florida-based partnership is all about breaking down those bureaucratic firewalls between patient care and controlled substances tracking. They’re pushing for a seamless workflow, where crucial...

Vortex Expands UK Reach with Torrent Acquisition Boost

Vortex's Ambitious UK Expansion A seasoned investor keen on infrastructure plays would find Vortex Companies’ latest move significant—not just another acquisition, but a realigned strategy for dominance as Britain braces for an infrastructure overhaul. With Torrent Drainage Services in their pocket, the Vortex Group plans to amp up its trenchless rehabilitation...

University of Phoenix Grads Shine in Job Readiness

University of Phoenix Graduates Proving Their Worth Dive straight into the world of University of Phoenix grads, and you're looking at some folks who seem to have the workplace game figured out. A fresh Harris Poll, done on behalf of the University itself, paints a rosy picture of these graduates from the eyes of those who actually supervise them. Turns out, managers are...

FSS Unveils AI Tool to Simplify Bankruptcy Cases

AI Revolution in Bankruptcy Management Alright, folks, there's a fresh breeze blowing in the bankruptcy management world, and it bears the acronym FSS. Financial Software Solutions is rolling out its innovative FSS Intelligence Engine. This little powerhouse aims to turn what used to be a gut-wrenching slog through mountains of paperwork into a slick, automated process....

Roof Replacement Timelines: Key Insights for PA Homeowners

There's no denying it; having a roof over your head is one thing, but knowing when to replace it is a whole other ballgame. In Pennsylvania, where the weather loves to throw curveballs, making the right call on roof replacement can save a heap of trouble down the road. Thanks to Miguel Cornejo and his insights in HelloNation’s latest rundown, we get a clearer picture of...

OSHA and NSC Forge Alliance to Prevent Worksite Tragedies

Forging Ahead With a Crucial Collaboration Ins, outs, ups, and downs—safety shouldn’t get lost in the shuffle, but it does. In steps the National Serious Injury and Fatality Prevention Alliance, a fresh partnership convened by OSHA with the National Safety Council—hop on board or get left behind mindsets. We’re talking about real, heads-down, hard-hitting actions...

Medicare Payment Proposal Faces Doctor Backlash in D.C.

Why Same-Day Medicare Care Matters Imagine you're gasping for breath, struggling to find relief, and then being told to wait weeks for care. It's not just an inconvenience; it's a health hazard. This isn't some arbitrary tale—it's the gritty reality for folks relying on same-day care. A group of docs and advocates recently stormed Capitol Hill sounding the alarm about a...

Crucial Insights for South GA Home Insurance Choices

Understanding the Insurance Jargon Here we go again, dealing with insurance gobbledygook that’s about as clear as mud to most of us. Homeowners in South Georgia are being urged to pay attention to the differences between replacement cost and actual cash value in their insurance policies. This ain't just legalese, folks—it's your protection when disaster strikes in our...

JennAir and Cosentino Introduce Seamless Kitchen Aesthetics

It's not every day that the kitchen landscape gets a bold makeover, but JennAir and Cosentino seem to think it's time. Introducing their latest splash, the JennAir x Dekton panel collection is here to redefine what luxury kitchens can look like—an embodiment of seamless beauty that’s more sculpture than cooking space. Elevating Kitchen Design So, what's the buzz about...

Superga and Pasqua's Unlikely Fashion-Vineyard Fusion

Superga and Pasqua: A Fusion of Fashion and Vineyards Here's one for the books: Superga, the storied Italian footwear maestro, teaming up with Pasqua Wines, straight out of Verona’s vineyard heartland. On the surface, it seems a rather odd coupling. One's got rubber soles; the other’s got corks. But they’ve pulled off a daring bedroom switch, creating a...